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Src family kinases (SFK) play a central signaling role for growth factors, cytokines, G-protein-coupled receptors and other stimuli. SFKs play
important roles in pancreatic acinar cell secretion, endocytosis, growth, cytoskeletal integrity and apoptosis, although little is known of the specific
SFKs involved. In this study we demonstrate the SFK, Lyn, is present in rat pancreatic acini and investigate its activation/signaling. Ca2+-mobilizing
agents, cAMP-mobilizing agents and pancreatic growth factors activated Lyn. CCK, a physiological regulator of pancreatic function, rapidly
activated Lyn. The specific SFK inhibitor, PP2, decreased Lyn activation; however, the inactive analogue, PP3, had no effect. Inhibition of CCK-
stimulated changes in [Ca2+]i decreased Lyn activation by 55%; GFX, a PKC inhibitor by 36%; and the combination by 95%. CCK activation of Lyn
required stimulation of high and low affinity CCKA receptor states. CCK stimulated an association of Lyn with PKC-δ, Shc, p125
FAK and PYK2 as
well as with their autophosphorylated forms, but not with Cbl, p85, p130CAS or ERK 1/2. These results show Lyn is activated by diverse pancreatic
stimulants. CCK's activation of Lyn is likely an important mediator of its ability to cause tyrosine phosphorylation of numerous important cellular
mediators such as p125FAK, PYK2, PKC-δ and Shc, which play central roles in CCK's effects on acinar cell function.
Published by Elsevier B.V.Keywords: Pancreas; src; src kinase; lyn; Cholecystokinin; Pancreatic secretion; Pancreatic growth; Pancreatic growth factor1. Introduction
The Src family of kinases (SFK) consists of nine structurally-
related peptide members [1,2]. They are activated by a wide
range of stimuli including antigens, growth factors, oxidative
stress, integrins, and some G protein-coupled receptors [1,2].
SFK's function as key signaling molecules for the changes in
cellular function produced by these stimuli including growth,
gene transcription, secretion, adhesion, and apoptosis [1]. The
SFK members (c-Src, Fyn and Yes) are widely expressed in
different tissues, whereas the others (including Lyn, Hck, Fgr,
Blk, Yrk) have a more restrictive distribution [2]. In pancreatic
acinar cells, SFKs are reported to be important in cell growth and⁎ Corresponding author. NIH/NIDDK/DDB, Bldg. 10, Rm. 9C-103, 10 Center
DR MSC 1804, Bethesda, MD 20892-1804, USA.
E-mail address: robertj@bdg10.niddk.nih.gov (R.T. Jensen).
0167-4889/$ - see front matter. Published by Elsevier B.V.
doi:10.1016/j.bbamcr.2006.03.004the cellular effects of various growth factors [3]. In addition, in
pancreatic acini, SFKs play an important role in enzyme
secretion, membrane recycling, endocytosis, apoptosis, protein
synthesis in regulating cellular calcium levels, in regulation of
PKCs, in response to injury such as pancreatitis, and in
maintaining cytoskeletal organization [4–11]. At present little
is known about the specific SFKs involved in these different
pancreatic cellular responses. In pancreatic acinar cells the SFKs
reported to be present are Yes [7,10]; pp60c-Src in some studies
[7] but not others [10]; and in two studies, Lyn [9,10]. Whereas a
number of studies have examined activation of pp60Src or Yes in
gastrointestinal tissues including pancreas [4,5,7,8,10,11], there
is almost no information on Lyn activation by gastrointestinal
hormones/neurotransmitters or growth factors that alter acinar
pancreatic cell function.
The SFK, Lyn, was originally discovered in hematopoietic
cells [12] and almost all the early studies of Lyn were in these
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effects on proliferation, differentiation, immune responses and
receptor-mediated signaling [12]. Recent studies report Lyn's
presence in a number of nonhematopoietic cells [9,13]. In
general, little is known of Lyn's function in nonhematopoietic/
immune tissues such as the pancreas. Some recent studies
suggest Lyn may have important effects on survival/growth in
some of these cells because it has been shown to function as a
negative regulator of apoptosis in a number of cell systems
[13,14].
The purpose of the present study was to address these issues
by studying the activation of Lyn by various gastrointestinal
hormones/neurotransmitters and growth factors and its cell
signaling in response to one of the main pancreatic hormones,
CCK, in pancreatic acinar cells. This cell system is an excellent
model to examine these relationships because it has been shown
to be highly responsive to many gastrointestinal hormones/
neurotransmitters and growth factors which alter pancreatic
acinar function and has been extensively used to study the
effects of these stimulants on cell signaling cascades including
activation of phospholipases (A, C, D), adenylate cyclase and
tyrosine kinase cascades [6,9,15–17].
2. Experimental procedures
2.1. Materials
Male Sprague–Dawley rats (150–200 g) were obtained from the Small
Animals Section, Veterinary Resources Branch, National Institutes of Health
(Bethesda, MD). Purified collagenase (type CLSPA) was from Worthington;
COOH-terminal octapeptide of cholecystokinin (CCK-8) was obtained from
Peninsula Laboratories (Belmont, CA); CCK-JMV was obtained from Research
Plus Inc., (Bayonne, NJ); Secretin, VIP, Endothelin-I, Hepatocyte Growth
Factor (HGF), bFGF, Insulin, IGF-1, were from Bachem (Torrence, CA),
phosphate-buffered saline, pH 7.4, was from Biofluids (Rockville, MD);
Tyrosine kinase assay kit (non-radioactive) was from Upstate (Lake Placid, NY);
phosphorylation-site specific pAb (anti-pY402 PYK2, anti-pY397 FAK, anti-
pY418 Src) were from Biosource International (Camarillo, CA); goat anti-rabbit
IgG horseradish peroxidase conjugate, mAb anti-Lyn, pAb anti-Lyn and Lyn
Blocking Peptide, pAb anti-pp60Src, pAb anti-Yes, mAb anti-pp60Src, mAb
anti-Yes were from Santa Cruz Biotechnology (Santa Cruz, CA); anti-
phosphotyrosine mAb, anti- PKC-δ pAb, anti-FAK mAb and anti-PYK2 mAb
and anti-Shc Ab were from BD Transduction Laboratories (Lexington, KY);
platelet derived growth factor (PDGF), epidermal growth factor (EGF), PP2 (4-
amino-5[4-chlorphenyl]-7-pyrazol [3,4-d]pyrimidine) and PP3 (4-amino-7-
phenylpyrazol [3,4-d]pyrimidine) were from Calbiochem (La Jolla, CA).
Other reagents were from sources described previously [9,17,18].
2.2. Methods
2.2.1. Tissue preparation
Dispersed rat pancreatic acini were prepared according to the modifications
of the procedure published previously [19]. Unless otherwise stated, the
standard incubation solution contained 25.5 mM HEPES (pH 7.4), 98 mM
NaCl, 6 mM KCl, 2.5 mM NaH2 PO4, 5 mM sodium pyruvate, 5 mM sodium
fumarate, 5 mM sodium glutamate, 11.5 mM glucose, 0.5 mM CaCl2, 1 mM
MgCl2, 2 mM glutamine, 1% (w/v) albumin, 1% (w/v) trypsin inhibitor, 1% (v/
v) vitamin mixture and 1% (w/v) amino acid mixture. The incubation solution
was equilibrated with 100% O2 and all incubations were performed with 100%
O2 as the gas phase. Dispersed acini from one or two rats were preincubated with
standard incubation solution without or with different inhibitors for 3 h at 37 °C.
Aliquots (1 ml) were then incubated at 37 °C with different agonists at the
concentrations and times indicated. Acinar lysates were obtained as describedpreviously [16,20]. Protein concentration was measured by the Bio-Rad protein
assay reagent as described previously [19].
2.3. Immunoprecipitation tyrosine kinase assay
Immunoprecipitation of tyrosine phosphorylated proteins
was performed as described previously [16]. For detection of
p60 Src, Yes and Lyn, acinar lysates (900 μg/ml for p60 Src,
600 μg/ml for Yes, 300 μg/ml for Lyn) were incubated with 5 μg
p60Src pAb, 4 μg Yes pAb, and 4 μg Lyn pAb. For the Lyn-
blocking peptide experiments, a 120-min preincubation period
with 8 μg/ml Lyn blocking peptide was performed. For
detection of tyrosine phosphorylation of Lyn, acinar lysates
(200-400 μg/ml) were incubated with 3.75 μg of anti-Lyn mAb
or with 4 μg of anti-phosphotyrosine mAb (PY20) and 30 μl of
Protein G-agarose overnight at 4 °C. For Lyn-co-immunopre-
cipitation studies acinar lysate (200-400 μg/ml) were incubated
with 3.75 μg of anti-Lyn mAb and 30 μl of Protein-G-agarose
overnight. The immunoprecipitates were washed three times
with phosphate buffered saline and further analyzed by SDS-
polyacrylamide gel electrophoresis (PAGE) and Western
blotting.
In vitro tyrosine kinase assay- After incubation with CCK-
8 (1 or 10 nM) for 30s or with TPA (1 μM) for 5 min, pancreatic
acini were lysed and Lyn was immunoprecipitated as described
above. The immunoprecipitates were washed two times with
lysis buffer and two times with tyrosine kinase reaction buffer
(20 mM Tris–HCl pH 7.4, 10 mMMgCl2, 1 mMMnCl2, 1 mM
DTT, 0.2 mM ATP) and resuspended in 50 μl of tyrosine kinase
reaction buffer supplemented with 0.25 μg poly (Glu4-Tyr)
peptide, biotin conjugated and 1 mM sodium orthovanadate.
After 30 min incubation at 30 °C with vigorous shaking the
reaction was stopped by heat inactivation (5 min at 95 °C).
Phosphotyrosine was detected in a direct ELISA assay using a
1:100.000 dilution of anti-phosphotyrosine, recombinant 4G10,
HRP conjugate as described by the manufacturer (Tyrosine
Kinase Assay Kit, Upstate #17-315).
2.3.1. Western blotting
Western blotting was performed as described previously
[16,17,20]. Immunoprecipitates were subjected to 10% SDS-
PAGE; proteins were transferred to nitrocellulose membranes
(0.45 and 0.2 μm for proteins higher and lower than 60 kDa,
respectively). Membranes were blocked for one h at room
temperature and incubated for 2 h at room temperature or
overnight at 4 °C with 1 μg/ml anti-PYK2 pAb, 0.07 μg/ml anti-
pAb, 0.5 μg/ml anti-PYK2 mAb, 0.25 μg/ml anti-mAb, 4 μg/ml
anti-c-Src mAb, 0.2 μg/ml anti-Lyn mAb, 1 μg/ml anti-Yes pAb
or for 3 h at room temperature with 0.5 μg/ml anti-pAb or 1 μg/
ml anti-Shc-Ab overnight. Membranes were washed twice and
incubated 1 h at 25 °C with goat anti-rabbit IgG-HRP conjugate
when a polyclonal antibody was used, or for 45 min with anti-
mouse IgG-HRP conjugate. Proteins were visualized using ECL
reagents and Hyperfilm ECL and the density of bands was
measured using a Kodak Imaging System (Kodak Imaging
System 440 CF, Kodak, Rochester, NY). When reprobing was
necessary, membranes were stripped of bound antibodies and
Fig. 1. Identification of Src-family members in pancreatic acinar cells. Whole
cell lysates were immunoprecipitated with anti-pp60Src pAb, anti-Yes pAb,
anti-Lyn pAb, or anti-Lyn pAb after being incubated for 120 min with Lyn
blocking-peptide. Western blotting (WB) was performed as described in
Methods with anti-pp60Src mAb (lane 1), anti-Yes mAb (lane 2), anti-Lyn mAb
(lanes 3 and 4). The bands were visualized using ECL. This figure is
representative of two others.
Fig. 2. Site-specific tyrosine phosphorylation of Lyn stimulated by secretago-
gues, growth factors and post-receptor stimulants. Rat pancreatic acini were
treated with the different stimulants as shown in the figure and then lysed. After
immunoprecipitation with anti-Lyn mAb, Western blotting (WB) was performed
with anti-pSrc (pY418) pAb and visualized as described in the legend to Fig. 1.
The upper panel shows the site-specific Lyn tyrosine phosphorylation
(pY418Lyn) after stimulation with various pancreatic secretagogues, the middle
WB after stimulation with growth factors, and the bottom WB after stimulation
with post-receptor stimulants. The bottom part of each panel shows the protein
loading control assessed with Lyn mAb after stripping the membranes. Each
experiment is representative of at least three others.
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loading was verified using Lyn mAb.
3. Results
To verify that the antibodies used detected SFKs in
pancreatic acini, we immunoprecipitated whole cell lysates
with specific polyclonal antibodies (anti-pp60Src-, anti-Yes-
and anti-Lyn-Ab) and then analyzed by Western blotting with
specific monoclonal antibodies (Fig. 1). We identified pp60Src,
Yes and Lyn using these specific antibodies (Fig. 1). We distin-
guished Lyn in pancreatic acini by its different molecular weight
from the other two Src-kinases, pp60Src and Yes (Fig. 1). Lyn
showed the characteristic double band corresponding to its two
isoforms at 53 kDa and 56 kDa, as seen in other tissues. A
specific blocking peptide for Lyn abolished its signal (Fig. 1,
compare lanes 3 and 4).
Numerous studies show that Lyn and the other SFKmembers
share two tyrosine phosphorylation sites, one (Y418), causing
the activation of these kinases, the second (Y527), causing its
inhibition, both through a conformational change of the kinases
[1]. Y418 phosphorylation of SFKs has been shown to reflect the
degree of activation of SFKs [22] and therefore was used to
assess specific Lyn activation by first specifically immunopre-
cipitating Lyn. Receptor-mediated secretagogues known to
activate phospholipase C (PLC) (CCK, carbachol, bombesin)
[15,23] as well as post-receptor stimulants directly activating
PKC (TPA) or mobilizing cellular calcium [thapsigargin (TG) or
calcium ionophore (A23187)] (bottom panel) [15], each
activated Lyn (Fig. 2). The combination of a calcium-mobilizing
agent (TG, A23187) with a PKC activator (TPA) caused no
greater activation of Lyn than with either agent alone (Fig. 2,
bottom panel, lanes 1-6). Specifically, TPA (1 μM) and TPA(0.3 μM) caused a 4.3±0.5 (Fig. 2) and 2.6±0.2 (data not
shown) fold activation of Lyn, respectively; A23187 (1 μM)
caused a 3.9±1.4 fold increase (Fig. 2) and the combination of
A23187 and TPA (1 μM or 0.3 μM) caused a 3.6±0.3 fold
increase (Fig. 2) and a 2.9±0.2 fold increase (data not shown) in
Lyn activation. Endothelin-1 (Et-1), which interacts with Et-1
and Et-3 receptors on acini but does not activate PLC cascades or
cause a known change in cellular signaling [15,24], caused
minimal activation of Lyn (Fig. 2, top panel, lane 7).
Secretagogues interacting with G protein-coupled receptors
and activating adenylate cyclase in pancreatic acini (VIP,
Fig. 3. Time course of site-specific tyrosine phosphorylation of Lyn stimulated
by CCK-8 in rat pancreatic acini. Rat pancreatic acini were treated with CCK-
8 (10 nM) for the indicated times and then lysed. After immunoprecipitation
with anti-Lyn mAb, Western blotting was performed with anti-pSrc (pY418)
pAb and visualized as described in the legend to Fig. 1. The upper part shows
results from a representative experiment and the protein loading control assessed
with Lyn mAb after stripping membranes. The values shown in the bottom part
are the means±S.E. of nine experiments and are expressed as fold increase over
the pretreatment level (experimental/control).
Fig. 5. Ability of CCK-8 and TPA to increase relative Lyn kinase activity in rat
pancreatic acini. Rat pancreatic acini were incubated for 30 s with 1 or 10 nM
CCK-8 or for 5 min with 1 μM TPA and then lysed. Lyn immunoprecipitated
were resuspended in tyrosine kinase reaction buffer with 0.25 μg poly(Glu4-Tyr)
peptide biotinylated and incubated for 30 min at 30 °C. In vitro kinase assay and
phosphotyrosine detection were performed as described in Methods. The values
of relative Lyn kinase activity are the means±S.E. of four experiments in
duplicate and are expressed as the fold-increase as a ratio of the experi-
mental value over the control value without addition. The maximal increase was
4.5±0.65 fold. *Pb0.05 compared to control.
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activation of Lyn (Fig. 2, top panel, lanes 5 and 6; bottom panel,
lane 7). Various growth factors known to alter pancreatic acinarFig. 4. Concentration-dependence of CCK-8 and CCK-JMV stimulation of the
site-specific tyrosine phosphorylation of Lyn in rat pancreatic acinar cells. Rat
pancreatic acini were treated for 0.5 min with the indicated CCK-8 and CCK-
JMV concentrations and then lysed. After immunoprecipitation with anti-Lyn
mAb, Western blotting was performed as described in the legend to Fig. 1. The
upper part shows results from a representative experiment and the protein
loading control assessed with Lyn mAb after stripping membranes. The values
shown in the bottom part are the means±S.E. of nine experiments and are
expressed as the percentages of maximal increase caused by 10 nM CCK-
8 above control unstimulated values. The maximal increase was 4.4±1.3 fold.
Fig. 6. Calcium-and PKC-dependence of CCK-8 stimulation of site-specific
tyrosine phosphorylation of Lyn. Rat pancreatic acini were pretreated for 30 min
at 37 °C in a calcium-free medium in presence of thapsigargin alone (1 μM) or
with GF109203X (5 μM) and in a calcium-containing medium with or without
GF109203X. Acini were then stimulated with 1 nM CCK-8 and then lysed.
After immunoprecipitation with anti-Lyn mAb, Western blotting was performed
as described in the legend to Fig. 1. The upper part shows results from a
representative experiment and the protein loading control assessed with Lyn
mAb after stripping membranes. The values shown in the bottom part are the
means±S.E. of seven experiments and are expressed as the percentages of
maximal increase caused by 1 nM CCK-8 above control unstimulated values.
Fig. 7. Association between Lyn, the focal adhesion kinases, FAK and PYK2
and their autophosphorylated forms. Rat pancreatic acini were treated with
CCK-8 (10 nM) for 0.5 min or TPA (1 μM) for 5 min and then lysed. After
immunoprecipitationWestern blotting (WB) was performed with anti-FAKmAb
(top panel), anti-pY397FAK (second panel), anti-PYK2 (third panel), anti-
pY402PYK2 (bottom panel) and visualized as described in the legend to Fig. 1.
Results are representative of two other experiments.
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caused activation of Lyn (Fig. 2, middle panel).
Because CCK is one of the principal physiological stimuli of
pancreatic acinar function [25], in the remainder of the study,
we concentrated on its ability to activate Lyn. The increase in
pY418 tyrosine phosphorylation caused by CCK was rapid and
its time course of tyrosine phosphorylation was biphasic, with
an initial rapid increase and then a decrease (Fig. 3). The
maximal increase occurred after 30 s and was 4.1±0.4-fold;
however, even after a 15-min incubation with CCK-8 when
tyrosine phosphorylation of Lyn had decreased 63%, it still hadFig. 8. The effect of the Src-inhibitor PP2 and its inactive analog PP3 on the associat
FAK and PYK2. Rat pancreatic acini were pretreated for 60 min with no additions, 2
After immunoprecipitation with anti-Lyn mAb,Western blotting was performed with
Fig. 1. This result is representative of two others. The bottom part shows mean±S.E
10 nM CCK-8 stimulation.not returned to control values, remaining 80±10% over the
control value (Fig. 3). By 30 min, the CCK-induced Lyn
tyrosine phosphorylation was not different from the basal level
(Fig. 3) and a similar result was seen 60 min after stimulation
(data not shown). The effect of CCK-8 on pY418 tyrosine
phosphorylation of Lyn was concentration-dependent (Fig. 4).
CCK-8 caused a detectible effect at 1 pM, a maximal effect at
1 nM and a half-maximal effect at 0.08±0.01 nM (Fig. 4) on
Lyn activation. CCK-JMV, an agonist at only the CCKA high
affinity receptor state [26] stimulated activation of Lyn in a
concentration-dependent manner (Fig. 4), causing a detectible
effect at 0.1 nM, a maximal effect at 0.1 μM and a half-maximal
effect at 1.2±0.4 nM (Fig. 4). CCK-JMV was not as efficacious
as CCK-8, with a CCK-JMV concentration of 0.1 μM, causing a
maximal response that was 58%±6% of the maximal CCK-
8 stimulated pY418 tyrosine phosphorylation of Lyn (Fig. 4).
An assessment of in vitro Lyn kinase activity was performed
in immunoprecipitates of pancreatic acini to show the
correlation between pY418 tyrosine phosphorylation of Lyn,
measured by Western blotting, with the relative Lyn kinase
activity, measured by a direct ELISA assay. CCK-8 (1 nM)
caused maximal increase in Lyn kinase activity (Fig. 5) similar
to the maximal increase observed in pY418 tyrosine phosphor-
ylation of Lyn cause by the same CCK-8 concentration (Fig. 4),
4.5±0.65 vs. 4.4±1.3, respectively. Moreover, TPA (1 μM)
caused a similar fold increase in pY418 tyrosine phosphoryla-
tion of Lyn (4.3±0.5 Fig. 2) and in Lyn kinase activity (3.5±
0.45 Fig. 5). Our results shown that pY418 tyrosine
phosphorylation of Lyn reflect the degree of activation of
Lyn, as previously described for this family of tyrosine kinases
[22].ion between Lyn and the autophosphorylated sites of the focal adhesion kinases
0 μg PP2, or 20 μg PP3 and then incubated with 10 nM CCK-8 and then lysed.
anti-pY397FAK or anti-pY402PYK2 and visualized as described in the legend to
. from three experiments, expressed as percent of maximal increase caused by
Fig. 9. The effect of the Src-inhibitor PP2 and its inactive analog PP3 on CCK-
8 and TPA stimulation of site-specific Lyn tyrosine phosphorylation in rat
pancreatic acinar cells. The experimental conditions were as described in Fig.
8 legend. After immunoprecipitation with anti-Lyn mAb, Western blotting was
performed as described in the legend to Fig. 1. The upper part shows results from
a representative experiment and the protein loading control assessed with Lyn
mAb after stripping membranes. This experiment is representative of three
others. The values shown in the bottom part are the means±S.E. of four
experiments and are expressed as fold increase over the pretreatment level
(experimental/control).
Fig. 10. CCK-and TPA-stimulated association of Lyn with Shc and PKC-δ. Rat
pancreatic acini were treated with CCK-8 (10 nM) for 0.5 min or TPA (1 μM) for
5 min and then lysed. After immunoprecipitation with anti-Shc pAb (top panel)
or anti-PKC-δ pAb (bottom panel), Western blotting (WB) was performed with
anti-Lyn mAb. Results are representative of two other experiments.
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which promotes the hydrolysis of phosphatidylinositol 4,5-
bisphosphate, leading to the generation of inositol phosphates
that stimulate cellular calcium mobilization and to the
production of diacylglycerol which activates PKCs. [15,26].
We next examined whether CCK-8 induced activation of PKC
or increase in intracellular calcium, or both, were needed for its
ability to cause pY418 tyrosine phosphorylation of Lyn in
pancreatic acini (Fig. 6). To determine the role of intracellular
calcium changes [Cai], pancreatic acinar cells were pretreated
for 30 min in a calcium-free medium with thapsigargin (10 μM),
an agent that specifically inhibits the endoplasmic reticulum
Ca2+-ATPase and depletes calcium from intracellular compart-
ments [17]. These conditions have been shown to completely
inhibit the [Ca2+]i increase stimulated by CCK-8 in rat
pancreatic acini [17]. To determine whether PKC activation
might be involved in mediating CCK-8-stimulated increases in
pY418 tyrosine phosphorylation of Lyn, we examined the effect
of a PKC inhibitor, GF109203X [17]. Thapsigargin in a
calcium-free media inhibited CCK stimulation of pY418
tyrosine phosphorylation of Lyn by 55±8% (Fig. 6, compare
lanes 2 and 3). The inhibition of PKC activation by CCK
reduced pY418 tyrosine phosphorylation of Lyn by 35±26% of
the maximal stimulation caused by CCK-8 (Fig. 6, comparelanes 2 and 4). The simultaneous inhibition of both a CCK-
stimulated increase in intracellular calcium and PKC activation
by the combination of GFX109203X and thapsigargin in a
calcium-free media caused an additive effect, inhibiting the
pY418 tyrosine phosphorylation of Lyn by 95±4% of the
maximal stimulation caused by CCK-8 (Fig. 6, lane 5).
Recent studies demonstrate CCK can stimulate activation
and tyrosine phosphorylation of focal adhesion kinases
(p125FAK and PYK2) in pancreatic acini [16,17,19]. Src
family kinases can bind to the autophosphorylation sites of
these kinases [p125FAK (pY397) and PYK2 (pY402)] and
stimulate their activation in a number of other tissues [27]. To
determine whether CCKA receptor activation could stimulate
an association of Lyn with the focal adhesion kinase, p125FAK
and PYK2, we assessed the formation of complexes between
Lyn and these proteins by performing co-immunoprecipitation
studies (Fig. 7). Stimulation with CCK-8 or the phorbol ester,
TPA stimulated Lyn association with both focal adhesion
kinases p125FAK and PYK2 (Fig. 7). CCK-8 and TPA also
stimulated the association of Lyn with the autophosphorylated
form of p125FAK (pY397) as well as the autophosphorylated
form of PYK2 (pY402) (Fig. 7). To investigate whether in
pancreatic acinar cells association of Lyn kinase with focal
adhesion kinases is dependent on activation of Lyn, we used
PP2, a specific inhibitor for Src tyrosine kinases, and its inactive
analog, PP3, as a negative control [28]. Acini were pretreated
for 60 min with PP2 (20 μM) or with PP3 (20 μM) and then
incubated with 1 nM CCK-8 for 0.5 min or with 1 μM TPA for
5 min. Pretreatment of pancreatic acini with PP2 caused a
complete inhibition of the association of Lyn with p125FAK
(pY397) (Fig. 8, left panel) or PYK2 (pY402) (Fig. 8, right
panel) induced by both CCK-8 and TPA. Pretreatment with PP3
under identical experimental conditions did not modify both
basal or CCK-8- and TPA-stimulated association of Lyn with
p125FAK (pY397) (Fig. 8, left panel) and PYK2 (pY402) (Fig.
8, right panel), demonstrating the specificity of the PP2. To
confirm that PP2, and not PP3, were actually inhibiting
activation of Lyn by CCK or TPA, pY418 tyrosine phosphor-
ylation of Lyn was assessed after stimulation with CCK or TPA
in the presence or absence of PP2 or PP3 (Fig. 9). PP2 (20 μM)
caused a 68±17% inhibition of CCK and 60±10% inhibition of
TPA-stimulated pY418 tyrosine phosphorylation of Lyn,
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(Fig. 9).
CCK is reported to activate MAP kinases in pancreatic acini
[29] as well as the novel protein kinase C, PKC-δ, in addition to
stimulating its tyrosine phosphorylation and translocation [9]. In
a number of tissues, Src kinases are reported to play a role in the
activation of Shc and/or PKC-δ by various stimuli and increase
the association of Src with these proteins [9,30]. Recently, both
TPA and CCK in pancreatic acini are reported to stimulate the
interaction of PKC-δ with a Src kinase and evidence was
provided that Lyn was at least partially involved [9]. To
determine whether CCKA receptor activation could stimulate an
association in pancreatic acini between SFKs and Shc, and to
confirm the previous study reporting an increased association
between PKC-δ and Lyn [9], we performed co-immunoprecip-
itation studies (Fig. 10). Both TPA and CCK stimulated an
association of Lyn with Shc and with PKC-δ (Fig. 10). Src
kinases are reported to associate [31,32] with a number of other
intracellular proteins in other cells including p130Cas, PI3K,
and Cbl. We assessed whether CCKA receptor activation or TPA
stimulation could stimulate such an association in pancreatic
acini using immunoprecipitation studies. Immunoprecipitating
with antibodies to p130Cas, Cbl, phosphoCbl, ERK 1/2, or the
p85 subunit of PI3K, and Western blotting with anti-Lyn
antibody, or performing studies with antibodies in the reverse
order, did not demonstrate any CCKA receptor or TPA-
stimulated association between Lyn kinase and these proteins
(data not shown).
4. Discussion
The present study was designed to address the question of
whether activation of the SFK, Lyn is involved in the cellular
signaling by various gastrointestinal growth factors and
gastrointestinal hormones/neurotransmitters that are known to
alter pancreatic acinar cell function. The effect of the hormone/
neurotransmitter, cholecystokinin (CCK), which is a physiolog-
ical regulator of pancreatic acinar cell function [25], was
investigated in detail since CCK is reported to activate other
SFKs such as Yes and pp60Src [5,10,11,17,33]. A number of our
results support the conclusion that the SFK, Lyn, is present in
pancreatic acinar cells. Lyn's presence was established by
Western blotting after immunoprecipitating with specific Lyn
antibodies. The expression of Lyn could be distinguished from
the two other SFKs expressed in pancreatic acini, pp60Src and
Yes, by their different molecular weights, and the detection of
characteristic p53 and p56 isoforms of Lyn, which have been
described in various tissues [12]. Furthermore, specific detection
of Lyn in pancreatic acinar cells by the Lyn antibody used was
supported by demonstrating the ability of a specific Lyn-
blocking peptide to abolish the Western blotting signal. Our
result is supported by findings in two other studies [9,10] which
report that pancreatic tissues contains a Lyn-like protein.
In the present study we assessed the ability of various
pancreatic stimulants to activate Lyn by assessing their ability to
stimulate pY418 tyrosine phosphorylation of Lyn. Our results
show that CCK, as well as a number of other pancreaticsecretagogues which activate G protein-coupled receptors on
pancreatic acinar cells and stimulate either phospholipase C
(PLC)-mediated, PKA-mediated pathways or other signaling
cascades [15], can activate Lyn in pancreatic acini. These results
have some similarities and differences from previous studies of
the ability of these GI hormones/neurotransmitters and other
stimulants to activate SFK in pancreatic acini and other tissues.
They are similar in that CCK has been reported to stimulate
SFKs in pancreatic acinar cells or AR42J pancreatic acinar
cancer cells [4–8,11,34] as well as bombesin-related peptides,
VIP, muscarinic cholinergic agents and secretin activate SFKs in
other tissues [1,35]. Endothelin has been shown to activate SFKs
in different cells [36,37]. Whereas in many cells, including
pancreatic acini, agents that activate PLC cascades have been
frequently shown to activate various SFKs, the ability of agents
that stimulate adenylate cyclase to activate various SFKs shows
marked differences in different studies. In some cells agents that
activate adenylate cyclase, stimulate SFK activation [38–40];
whereas in other cells agents that increase cyclic AMP decrease
SFK activation [41] or have no effect on SFK activation [42].
Our results demonstrate that Lyn is activated in pancreatic acini
by G protein-coupled receptors acting through diverse signaling
pathways including activation of adenylate cyclase and,
therefore, Lyn likely plays an important central role in signaling
by many GI hormones/neurotransmitters that alter pancreatic
acinar cell function.
Numerous growth factors (HGF, EGF, bFGF, insulin, IGF-1
and PDGF) have been shown to interact with specific receptors on
pancreatic acinar cells and stimulate growth and/or protein
synthesis as well as alter other cellular functions [15]. SFKs play
an important role inmediating the action of growth factors in other
tissues [1]. However little is known of the role of SFKs in growth
factor signaling in normal pancreatic acinar cells. Our study
demonstrates that each of the known pancreatic growth factors
(HGF, EGF, bFGF, insulin, IGF-1 and PDGF) activate Lyn in rat
pancreatic acini. Our results differ from a recent study [6] that
reported bFGF failed to stimulate SFKs in pancreatic acini.
Numerous studies demonstrate that the CCK can activate
both a high and low affinity receptor state which can mediate
different cellular responses [17,26]. A number of results support
the conclusion that CCK causes activation of Lyn by interacting
with both CCKA receptor states. The CCK dose-response curve
for Lyn activation extended over 5 log units which included the
concentration ranges it activates, both high and low affinity
receptor states [15], suggesting activation of both CCKA
receptor states are involved in Lyn activation. This conclusion
is supported by the results with CCK-JMV, a synthetic CCK
analogue that stimulated 60% of the maximal Lyn activation
caused by CCK-8. Because CCK-JMV in rat pancreatic acini
functions as a full agonist at the high affinity state and an
antagonist of the low affinity state [26], our results demonstrate
60% of Lyn activation is due to activation of the high affinity
CCKA receptor state and 40% to activation of the low affinity
CCK receptor state. These results have similarities and
differences from that reported in other studies in pancreatic
acini with CCKA receptor-mediated tyrosine phosphorylation of
other proteins, or stimulation of SFK activation. Similar to CCK
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phosphorylation in pancreatic acini of the focal adhesion kinases
(p125FAK, PYK2/CAβ) [17] or their phosphospecific sites
(pY402-, pY508-, pY881-PYK2; pY397-, pY577-, pY925-
FAK) [19]; and paxillin [16,17] is mediated by activation of both
high and low affinity receptor states. In contrast, CCK-
stimulated tyrosine phosphorylation of PKC-δ [9] or CrKII
[34] is mediated by activation of only the low affinity CCKA
receptor state. Also in contrast to a previous study [6] which
reported CCK-stimulated SFK activity is mediated almost
entirely by activation of the low affinity CCKA receptor state
in pancreatic acini, we found with CCK stimulation of Lyn
activation, at least 60% is through the high affinity CCKA
receptor state. These results provide additional support to the
proposal [43] that not only are the different CCKA receptor
states on pancreatic acini differentially coupled to activation of
phospholipase A2 and C [15], they are also differentially
coupled to a number of tyrosine phosphorylation cascades
including activation of Lyn.
Activation of the pancreatic CCKA receptor stimulates
phospholipase C (PLC), resulting in the generation of inositol
phosphates and diacylglycerol which in turn results in
mobilization of cellular calcium and activation of PKCs,
respectively [15,17]. Recent studies show activation of the two
limbs of the PLC cascade (i.e. PKC and cellular calcium) in
pancreatic acini and other cells by different stimuli, can have
different effects on the phosphorylation of non-receptor tyrosine
kinases such as the focal adhesion kinases, p125FAK and PYK2
[16,17]. There is only minimal information available on the
interaction with the PLC cascade and activation of SFKs in
pancreatic acinar cells. In one study [6] it was concluded that
CCK could activate SFKs in pancreatic acini only through its
activation of the low affinity CCKA receptor state, resulting in
mobilization of cellular calcium, whereas its activation of the
high affinity CCKA receptor state or PKC activation had no
effect on SFK activity. A number of our results support the
conclusion that in pancreatic acini CCK activation of Lyn
involves activation of both limbs of the PLC cascade. First,
agents that increased cellular calcium activated Lyn. Second,
activation of PKCs by TPA also activated Lyn. Third, incubation
with the Ca2+ATPase inhibitor, thapsigargin, which has been
shown to completely inhibit CCK-mediated increase in [Ca2+]i
in pancreatic acini [17], inhibited CCK-stimulated Lyn activa-
tion by 55%. Furthermore, the PKC inhibitor, GF109203X, at a
concentration that inhibited TPA-stimulated tyrosine phosphor-
ylation of other non-receptor tyrosine kinases such as p125FAK
and PYK2 [17,19] in rat pancreatic acini, caused a 36% decrease
in CCK-stimulated activation of Lyn. Fourth, the simultaneous
inhibition of both limbs of the PLC cascade by addition of
GF109203X and thapsigargin, completely inhibited Lyn activa-
tion, supporting the conclusion that CCK's activation of both
limbs of the PLC cascade are essential for full Lyn activation.
These results have similarities and differences from the role of
PKC activation and/or changes in cytosolic calcium by different
stimulants in other cells on activation of SFKs. Similar to the
effect of CCK in pancreatic acini, PKC activation or changes in
cytosolic calcium have been shown to be important for SFKactivation by a number of stimulants in different cells [44,45]. In
contrast, activation of SFKs in granulocytes is not dependent on
PKC activation [45], and bombesin activation of Src pathway in
3T3 cells is calcium-independent [44].
In other cells, activated SFKs are known to associate with and
alter the activity of many substrates including kinases,
cytoskeletal proteins, structural proteins, enzymes, adapters
and receptors [1]. Particularly important with some growth
factors and G-protein-coupled receptors are interactions with
focal adhesions kinases (p125FAK, PYK2) [1,27,44], paxillin
[1], p130CAS [1], PKC-δ [1], PI3-kinase [1], Shc
[1,30,33,46,47], and Cbl [1]. A number of our results support
the conclusion that CCK and TPA activation of Lyn in pancreatic
acini stimulates association with focal adhesion kinases as well
as with Shc and PKC-δ. First, CCK as well as TPA stimulated an
association of Lyn with p125FAK and PYK2 as well as with
pY397 p125FAK and pY402 PYK2, their specific autopho-
sphorylated forms [19,27]. Second, PP2 [28], a specific SFK
inhibitor, but not the related inactive analogue, PP3 [28],
inhibited the pY418 tyrosine phosphorylation of Lyn by CCK
and TPA and inhibited the association of Lyn with either pY397
p125FAK or pY402 PYK2. Third, immunoprecipitation studies
showed both CCK and TPA stimulated an association of Lyn
with Shc and PKC-δ but not with Cbl, ERK 1/2, the p85 subunit
of PI3K, or with p130CAS. Previous studies demonstrate CCK
activates ERK 1/2 [29], p130CAS [20], and PI3K [5] in pan-
creatic acinar cells; therefore, the failure to stimulate an
association of Lyn with these signaling molecules as reported
with Lyn and other SFKs in other cells [1] is not due to lack of
stimulation by CCK of these signaling pathways in pancreatic
acini. Previous studies have demonstrated in pancreatic acini
CCK stimulates activation of MAP kinases [29] via a signaling
cascade involving activation of PLC, resulting in mobilization of
cellular calcium, PKC activation and stimulation of tyrosine
kinases. CCK also stimulates formation of a Shc-Grb2-Sos
complex in pancreatic acini [46], which has been shown to play a
central role in MAP kinase activation. Lastly, a number of G-
protein-coupled receptors activateMAP kinases via activation of
PYK2 [17] and activation of CCKA receptor in pancreatic acini
stimulates a Grb2-PYK2 complex formation [17]. Our results
support the conclusion that the SFK, Lyn, may play a central role
in CCK activation of MAP kinase in pancreatic acini because
CCK stimulated both an association of Lyn with Shc as well as
PYK2, each of which activate MAP kinases [17]. These results
are similar to activation of a number of other G-protein-coupled
receptors which have been shown to stimulate MAP kinases by
similar mechanisms [48], and similar to results in neutrophils
with activation of chemoattractant receptors which stimulated a
complex formation between Lyn and Shc [47]. Recent studies
demonstrate CCK stimulates the translocation, activation, and
tyrosine phosphorylation of PKC-δ in pancreatic acini [9], which
is mediated by a Src-dependent mechanism [9], and this acti-
vation stimulates NFκ-B activity [49] which is important in
CCK-stimulated pancreatitis in these cells [49]. Our results
support the conclusion that the SFK, Lyn, is likely the SFK
involved because our results confirm the findings of a previous
study [9] that CCK stimulated the association of Lynwith PKC-δ.
364 A. Pace et al. / Biochimica et Biophysica Acta 1763 (2006) 356–365This result is consistent with studies in other cells where
stimulation by insulin, PKC activators, or growth factors is
reported to stimulate an association of Lyn or another SFK with
PKC-δ [9,50] but differ from results in PC-12 cells [51] or parotid
cells [51] where neither TPA nor carbachol stimulated an
association of PKC-δ and Src, although each activated PKC-δ
[9,50].
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